Maria Malamatari

Dr. Maria Malamatari

UCL School of Pharmacy, London, UK
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Drug Discovery Today
Verified
Journal Article
Closed access
Maria MalamatariMaria Malamatari
Maria Malamatari
KTKevin M.G. Taylor
Kevin M.G. Taylor
SMStavros Malamataris
Stavros Malamataris
Dennis DouroumisDennis Douroumis
Dennis Douroumis
Kyriakos KachrimanisKyriakos Kachrimanis
Kyriakos Kachrimanis

25 January 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Anna KaragianniAnna Karagianni
Anna Karagianni
Maria MalamatariMaria Malamatari
Maria Malamatari
Kyriakos KachrimanisKyriakos Kachrimanis
Kyriakos Kachrimanis
Cocrystals can be used as an alternative approach based on crystal engineering to enhance specific physicochemical and biopharmaceutical properties of active pharmaceutical ingredients (APIs) when the approaches to salt or polymorph formation do not meet the expected targets. In this article, an overview of pharmaceutical cocrystals will be presented, with an emphasis on the intermolecular interactions in cocrystals and the methods for their preparation. Furthermore, cocrystals of direct pharmaceutical interest, along with their in vitro properties and available in vivo data and characterization techniques are discussed, highlighting the potential of cocrystals as an attractive route for drug development.

6 July 2020 in Processes
Verified
Journal Article
Open access
PDF file
Maria MalamatariMaria Malamatari
Maria Malamatari
ACANASTASIA CHARISI
ANASTASIA CHARISI
MSMalamataris Stavros
Malamataris Stavros
Kyriakos KachrimanisKyriakos Kachrimanis
Kyriakos Kachrimanis
IOANNIS NIKOLAKAKISIOANNIS NIKOLAKAKIS
IOANNIS NIKOLAKAKIS
Nanoparticle-based therapeutics have been used in pulmonary formulations to enhance delivery of poorly water-soluble drugs, protect drugs against degradation and achieve modified release and drug targeting. This review focuses on the use of spray drying as a solidification technique to produce microparticles containing nanoparticles (i.e., nanoparticle (NP) agglomerates) with suitable properties as dry powders for inhalation. The review covers the general aspects of pulmonary drug delivery with emphasis on nanoparticle-based dry powders for inhalation and the principles of spray drying as a method for the conversion of nanosuspensions to microparticles. The production and therapeutic applications of the following types of NP agglomerates are presented: nanoporous microparticles, nanocrystalline agglomerates, lipid-based and polymeric formulations. The use of alternative spray-drying techniques, namely nano spray drying, and supercritical CO2-assisted spray drying is also discussed as a way to produce inhalable NP agglomerates.

1 August 2017 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Maria MalamatariMaria Malamatari
Maria Malamatari
SRSteven Ross
Steven Ross
Dennis DouroumisDennis Douroumis
Dennis Douroumis
SVSitaram Velaga
Sitaram Velaga

3 February 2016 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
Maria MalamatariMaria Malamatari
Maria Malamatari
SSSatyanarayana Somavarapu
Satyanarayana Somavarapu
KTKevin MG Taylor
Kevin MG Taylor
GBGraham Buckton
Graham Buckton
Introduction: Nanosuspensions combine the advantages of nanotherapeutics (e.g. increased dissolution rate and saturation solubility) with ease of commercialisation. Transformation of nanosuspension...

1 November 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
FTF. Toziopoulou
F. Toziopoulou
Maria MalamatariMaria Malamatari
Maria Malamatari
INI. Nikolakakis
I. Nikolakakis
Kyriakos KachrimanisKyriakos Kachrimanis
Kyriakos Kachrimanis